YALE ENDS TRANSITION TREATMENTS FOR MINORS – It follows similar announcements from Children’s Hospital Los Angeles and UChicago Medicine
In a major policy reversal, Yale Medicine and Yale New Haven Hospital have officially ended the use of transgender hormone treatments for patients under 19 years old. It’s the latest in a growing list of major medical centres across the United States making a quiet—but significant—retreat from gender transition procedures for minors.
Yale confirmed that it will no longer offer puberty blockers or cross-sex hormones to adolescents under its “gender-affirming” program, though it will continue offering mental health support and counselling services for patients. According to Yale, the decision follows a careful review of federal guidelines introduced earlier this year.
In a public statement, the institution explained: “We have been carefully monitoring federal executive orders and administrative actions relating to gender-affirming care for patients under age 19. After a thorough assessment of the current environment, we have made the very difficult decision to eliminate the medication treatment component of our program.”
Though Yale never offered surgeries for minors, the move marks a major departure from previous policies and signals growing caution within medical institutions regarding the ethics, legality, and long-term implications of transitioning children.
This decision follows similar announcements from Kaiser Permanente, Children’s Hospital Los Angeles, and UChicago Medicine—all spurred by one of President Donald Trump’s first executive orders upon returning to office.
